Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135408 · ClinicalTrials.gov registry record · Phase 2
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT00135408: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00135408 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 115 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00135408, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
Interventions
- DRUG Ipilimumab+ Placebo
- DRUG Ipilimumab+ Budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
What the finished NCT00135408 record still lists
NCT00135408 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab+ Placebo is the first listed.
NCT00135408 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00135408 about?
NCT00135408 is a clinical study titled "A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide". The purpose of the study is to determine Efficacy, Safety and Tolerability of MDX-010 (BMS-734016) administered with or without Prophylactic Oral Budesonide.
What is the current status of trial NCT00135408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2005-12. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00135408?
The interventions under investigation include: Ipilimumab+ Placebo (DRUG), Ipilimumab+ Budesonide (DRUG).
Who is sponsoring clinical trial NCT00135408?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00135408's enrollment target sits among peer trials
115 626th of 2000 higher than 1,374 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia